• Fabricio F Costa.
• Genomic Enterprise, Chicago, IL 60614, USA; DataGenno Interactive Research Ltda, Rua Gastão Machado 66, Edifício CME, Salas 503/504, Campos dos Goytacazes, Rio de Janeiro, RJ 28035-120, Brazil; 1871: DataGenno Interactive Research, 222 W. Merchandise Mart Plaza, 12th Floor, Suite 1212, Chicago, IL 60654, USA; Cancer Biology and Epigenomics Program, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center and Department of Pediatrics, Northwestern University's Feinberg School of Medicine, Chicago, IL 60614, USA. Electronic address: fcosta@luriechildrens.org.
• Drug Discov. Today. 2014 Apr 1; 19 (4): 433-40.

AbstractThe increasing availability and growth rate of biomedical information, also known as 'big data', provides an opportunity for future personalized medicine programs that will significantly improve patient care. Recent advances in information technology (IT) applied to biomedicine are changing the landscape of privacy and personal information, with patients getting more control of their health information. Conceivably, big data analytics is already impacting health decisions and patient care; however, specific challenges need to be addressed to integrate current discoveries into medical practice. In this article, I will discuss the major breakthroughs achieved in combining omics and clinical health data in terms of their application to personalized medicine. I will also review the challenges associated with using big data in biomedicine and translational science. Copyright © 2013 Elsevier Ltd. All rights reserved.

5 keywords...

hide…